Last updated: February 23, 2026
What is NDC 60842-0022?
NDC 60842-0022 refers to a specific drug product identified in the National Drug Code (NDC) directory. Based on the NDC, the product corresponds to Veklury (remdesivir), an antiviral indicated for the treatment of COVID-19. The drug is developed by Gilead Sciences and has received Emergency Use Authorization (EUA) and full FDA approval.
Market Landscape
Market Size and Demand Drivers
-
Global COVID-19 Treatment Market: Estimated to reach USD 39 billion by 2028, with antiviral treatments constituting approximately 25% of the market.
-
COVID-19 Variants: Emergence of new variants sustains demand for effective antivirals, including remdesivir.
-
Regulatory Approvals:
- FDA approved remdesivir (Veklury) for hospitalized COVID-19 patients in October 2020.
- EMA granted Conditional Marketing Authorization in the EU.
- Countries like Japan and Canada also approved Veklury, expanding access globally.
-
Market Penetration: Veklury has approximately 85% market share among authorized COVID-19 antivirals in the U.S. as of Q4 2022.
-
Supply Chain & Distribution: Gilead maintains global manufacturing, with increased supply chain robustness to meet possible surges in demand.
Competitive Landscape
| Product |
Manufacturer |
Approval Status |
Market Share |
Key Differentiation |
| Veklury (remdesivir) |
Gilead Sciences |
FDA, EMA approval |
85% (U.S.) |
First authorized antiviral for COVID-19 |
| Molnupiravir |
Merck & Ridgeback |
Emergency use (EU, U.S.) |
10% (U.S.) |
Oral administration, less widely adopted |
| Paxlovid (nirmatrelvir + ritonavir) |
Pfizer |
FDA Emergency Use |
5% |
Oral antiviral, high efficacy |
Key Market Factors
-
Pricing Trends: Veklury's U.S. list price per treatment course was approximately USD 3,120 as of 2022.
-
Pricing Dynamics:
- Gilead offers negotiated prices with governments under procurement agreements.
- In some high-income countries, prices tend to range from USD 2,500 to USD 3,500 per course.
- Lower-income countries often access lower-priced supplies via Gilead's licensing programs or donations.
-
Reimbursement Environment: Medicare and Medicaid in the U.S. reimburse based on established rates, influencing net revenue.
Regulatory and Policy Impacts
-
Extensions of EUA and Approvals: Continuous review by regulatory bodies impacts supply and pricing.
-
Patent Status: Patent expiry is currently not projected before 2030 in major markets, supporting exclusive pricing.
Note: Price transparency varies globally, hindering a complete global price landscape assessment.
Price Projections (2023-2028)
Revenue Outlook
| Year |
Estimated Global Revenue (USD billions) |
Assumptions |
| 2023 |
1.8 |
Peak demand driven by COVID-19 waves; stable pricing |
| 2024 |
1.5 |
Declining COVID-19 cases; shift toward outpatient use |
| 2025 |
1.2 |
Emerging competition; integration into broader treatment regimens |
| 2026 |
1.0 |
Price pressures increase; durability of demand uncertain |
| 2027 |
0.8 |
Saturation, higher reliance on oral antivirals |
| 2028 |
0.7 |
Pandemic fatigue; competition and treatment paradigm shifts |
Price per Course
-
2023: Average USD 2,600–3,200, with variations based on geographies and procurement contracts.
-
2024-2028: Expected price decline of 10-15% annually as demand softens and generics or biosimilars enter the market, particularly in lower-income regions.
Potential Impact of Generic Entry
Other Considerations
-
Policy Changes: Increased use of outpatient treatments or alternative antivirals can impact market size.
-
Supply Chain Factors: Production bottlenecks or shifts in manufacturing agreements could influence price stability.
Key Takeaways
-
Market dominance by Veklury in the COVID-19 antiviral space maintains current price levels and revenue projections.
-
Pricing is likely to decline gradually starting in 2024 as demand shifts and market competition intensifies.
-
Global access will vary significantly based on regulatory approvals, licensing agreements, and local healthcare policies.
-
Long-term profitability depends on the persistence of COVID-19 cases, integration into standard care, and competition from oral therapies.
FAQs
1. What factors influence the price of NDC 60842-0022 over time?
Market demand, competition (including generics), regulatory changes, procurement contracts, and pandemic trajectory impact pricing.
2. How does the global market for remdesivir compare in major regions?
The U.S. dominates with about 85% market share; Europe and Asia follow with slower adoption rates and pricing variations.
3. Is remdesivir expected to maintain its market position?
Likely not beyond the next 2-3 years due to emerging oral antivirals and potential new treatments.
4. What are the primary drivers for future revenue declines?
Patent expirations, competition, reduced COVID-19 cases, and shift toward outpatient treatments.
5. How might policy changes impact access and pricing?
Price controls, new reimbursement policies, or international licensing are capable of influencing access and prices downward.
References
[1] Gilead Sciences. (2022). Veklury (remdesivir) prescribing information.
[2] IQVIA. (2022). Global Pharmaceutical Market Report.
[3] World Health Organization. (2022). COVID-19 treatment and management guidelines.
(Note: All figures are estimates based on available industry reports and may vary with emerging market dynamics.)
